Uncategorized
Novartis’ Kisqali Secures Broad FDA Approval for Adjuvant Treatment of Early Breast Cancer
Kisqali, Novartis, FDA Approval, Early Breast Cancer, Adjuvant Treatment, HR+/HER2- Breast Cancer, CDK4/6 Inhibitors
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.
Nura Bio Secures $68 Million Funding for Neuroprotective SARM1 Inhibitor Development
Nura Bio, neuroprotective SARM1 inhibitor, $68M funding, pharmaceutical development, neuroprotection
Cigna’s Express Scripts Files Lawsuit Against FTC Over Allegedly Biased PBM Report
Express Scripts, FTC, PBM Report, Lawsuit, Biased, Erroneous, Drug Prices, Healthcare
FDA Issues Draft Guidance on Integrating Clinical Trials into Routine Clinical Practice and Enhancing Diversity in Clinical Studies
FDA, clinical trials, diversity, routine clinical practice, decentralized clinical trials, underrepresented populations, FDORA
CDMO Serán Secures $200M Investment from Bain Capital to Establish First Commercial Facility
CDMO Serán, Bain Capital, commercial facility, biopharmaceutical manufacturing, investment
FDA Updates Guidance to Combat Online Misinformation About Medical Products
FDA, online misinformation, medical products, guidance, regulatory clarity, public health
Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies
Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials
Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results
Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)
FDA Approves Lilly’s Ebglyss for Moderate-to-Severe Atopic Dermatitis
Ebglyss, atopic dermatitis, eczema, FDA approval, Eli Lilly, lebrikizumab, biologic treatment